Seres Therapeutics (MCRB) Research & Development (2016 - 2025)
Historic Research & Development for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $12.6 million.
- Seres Therapeutics' Research & Development fell 2335.36% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.2 million, marking a year-over-year decrease of 3286.77%. This contributed to the annual value of $64.6 million for FY2024, which is 4506.66% down from last year.
- As of Q3 2025, Seres Therapeutics' Research & Development stood at $12.6 million, which was down 2335.36% from $12.9 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' Research & Development ranged from a high of $46.8 million in Q2 2023 and a low of -$17.0 million during Q4 2022
- For the 5-year period, Seres Therapeutics' Research & Development averaged around $25.9 million, with its median value being $25.2 million (2023).
- Per our database at Business Quant, Seres Therapeutics' Research & Development tumbled by 14638.93% in 2022 and then surged by 23515.75% in 2023.
- Quarter analysis of 5 years shows Seres Therapeutics' Research & Development stood at $36.8 million in 2021, then plummeted by 146.39% to -$17.0 million in 2022, then soared by 235.16% to $23.0 million in 2023, then tumbled by 44.27% to $12.8 million in 2024, then dropped by 1.75% to $12.6 million in 2025.
- Its Research & Development stands at $12.6 million for Q3 2025, versus $12.9 million for Q2 2025 and $11.8 million for Q1 2025.